You just read:

DURECT Announces Completion of Enrollment in its Phase 2a Clinical Trial of DUR-928 in Psoriasis and 50% Enrollment in its Phase 1b DUR-928 Clinical Trial in NASH

News provided by

DURECT Corporation

Oct 07, 2019, 08:00 ET